Form 4: ZVRA CFO Renz Granted 300,000 Stock Options

Zevra Therapeutics' CFO, Justin Renz, was granted 300,000 stock options with an exercise price of $9.55, vesting over four years.

Summary

• Justin A. Renz, Chief Financial Officer of Zevra Therapeutics, Inc. (ZVRA), was granted 300,000 stock options.
• The options have an exercise price of $9.55 per share, which was equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the grant date.
• The grant date for these options was March 18, 2026.
• The options will vest and become exercisable in four equal annual installments, beginning on the first anniversary of the grant date (March 18, 2027), subject to Mr. Renz's continued service.
• All shares underlying the option will vest in full and become exercisable immediately prior to a change of control of Zevra Therapeutics.
• Vesting of the option will be accelerated by 12 months if Mr. Renz is terminated without cause or resigns for good reason.
• The options expire on March 17, 2036, ten years after the date of grant.
• The grant was made under the Issuer's 2023 Employment Inducement Award Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it strengthens the alignment of the CFO's financial interests with long-term shareholder value creation, a common and generally well-regarded practice in corporate governance.

Positives

• The grant of stock options aligns the financial interests of CFO Justin Renz with those of Zevra Therapeutics' shareholders, incentivizing long-term company performance.
• The vesting schedule, tied to continued service, promotes executive retention.
• Acceleration clauses for change of control or termination without cause provide standard executive protection.

Negatives

• The exercise of these options in the future could lead to dilution for existing shareholders if new shares are issued.

Risks

• The value of the options is dependent on the future market price of Zevra Therapeutics' common stock exceeding the $9.55 exercise price.
• Vesting is subject to the reporting person's continued service, meaning the options could be forfeited if employment ceases under certain conditions.
• Market volatility could impact the perceived value and eventual profitability of these options.

Future Outlook

This grant incentivizes the CFO to contribute to the long-term growth and success of Zevra Therapeutics, as the value of the options is directly tied to the company's stock performance.

Industry Context

StockSavvy.ai notes that the grant of stock options to key executives like a CFO is a standard practice in the biotechnology and pharmaceutical industries, including companies like Zevra Therapeutics, to attract, retain, and motivate talent. This aligns executive compensation with shareholder value creation, a common strategy across publicly traded companies.

Comparison to Industry Standards

• The structure of this stock option grant, including a multi-year vesting schedule and performance-based incentives (implied by stock price appreciation), is consistent with executive compensation packages observed at comparable small to mid-cap biotechnology firms.
• Similar grants are often seen at companies like Acadia Pharmaceuticals (ACAD) or Supernus Pharmaceuticals (SUPN) for their executive teams, where long-term equity incentives are crucial for aligning management with the often lengthy and risky drug development cycles.
• The exercise price being the closing price on the grant date is also standard practice for market-priced options.

Corporate Governance

Related Party Transactions

• This transaction represents an equity compensation grant from Zevra Therapeutics to its Chief Financial Officer, Justin Renz, who is considered a related party.

Stakeholder Impact

• Shareholders: Potential for increased alignment of management's interests with shareholder value, but also potential for future share dilution upon exercise of options.
• Employees: This grant may signal the company's commitment to retaining key talent and could set a precedent for other executive compensation.

Next Steps

• The stock options will vest in four equal annual installments, beginning on March 18, 2027.
• The CFO may exercise the vested options at any time before the expiration date of March 17, 2036, subject to company policy and insider trading regulations.

Key Dates

Keywords

ZEVRA, ZVRA, stock option, CFO, executive compensation, Form 4, insider transaction